Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 14
Submit an article Journal homepage
127
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma

Alexander GloverCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1252-5368
ORCID Icon,
Christopher P. FoxCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Andrew McMillanCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Amy BeechCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Nicholas Martinez-CalleCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Catherine GriffithsCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Faith RichardsonCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Nigel RussellCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
&
Mark J. BishtonCentre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
 show all
Pages 3529-3531 | Received 22 Jun 2020, Accepted 12 Aug 2020, Published online: 08 Sep 2020

References

  • Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Cin Oncol. 1995;13(3):588–595.
  • Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–418.
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
  • Lane AA, Armand P, Feng Y, Neuberg DS, et al. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012;53(6):1130–1136.
  • Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–3425.
  • Chantepie SP, Garciaz S, Tchernonog E, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018;93(6):729–735.
  • Martín A, Redondo AM, Valcárcel D, et al. Bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: final analysis of a phase 2 study from geltamo. Hematol Oncol. 2017;35:192–193.
  • Frankiewicz A, Saduś-Wojciechowska M, Najda J, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol. 2018;22(2):113–117.
  • Saleh K, Danu A, Koscielny S, et al. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma. 2018;59(11):2580–2587.
  • Tsang ES, Villa D, Loscocco F, et al. High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2019;54(3):481–484.
  • Modi D, Deol A, Ayash LL, et al. Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients. Support Care Cancer. 2017;25(8):2593–2601.
  • Yeshurun M, Vaxman I, Shargian L, et al. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect. 2018;24(7):749–754.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.